內 容
|
專題演講
邀請吳佳城博士蒞校分享其於抗體工程與癌症免疫治療領域之研究成果。吳博士擁有台灣大學免疫學博士學位，並曾於美國斯克里普斯研究所進行博士後研究，專精於抗體工程與癌症免疫治療。其研發的新藥 UCT021 是一種針對 GRP78 標靶的創新抗體藥物複合體（ADC），旨在治療急性骨髓性白血病，能精準殺傷急性骨髓性白血病（AML）細胞。本次演講將有助於提升師生對最新技術研發之學習與了解。
講師：吳佳城博士
最高學歷：台灣大學醫學院免疫學研究所博士
現任：友生泰生醫執行長
曾任：財團法人生物技術開發中心生物製藥研究所所長、台灣抗體協會監事、台灣抗體協會秘書長
專業領域與成就：
• 2017-2019 間主持/執行多項政府大型生醫計畫，年度經費約為3.6-4億元，包含11項抗體/次世代抗體新藥開發、 4項平台建立與配方/製程開發
• 10項新型專利發明人(申請/獲證)
• 2014、2016、2017 DCB “Technology Innovation Award”
• 2019 The 16th National Innovation Award
講題：UCT021, An Innovative Antibody Drug Conjugate Targeting GRP78 for Acute Myeloid Leukemia Therapy
時間：115年04月24日(週五)中午12:10∼13:40
地點：中央校區第一教學研討室
備註：
1.本研習活動採計慈濟大學《協助教師整體發展辦法》之『教師增能研習認列一次』
2.請進入校務行政系統報名【活動編號為:11500436】
3.完成報名且準時出席者提供限量簡易餐點。
4.校外人士報名請Email：fangting@gms.tcu.edu.tw，並提供姓名及單位
主辦單位：醫學系生理學科/生物醫學碩士班
經費來源：高教深耕計畫
**Special Lecture Announcement**
The Department of Physiology, School of Medicine, and the Master is Program in Biomedical Sciences at Tzu Chi University are pleased to announce a special lecture by Dr. Chia-Cheng Wu, who will share his research achievements in the fields of antibody engineering and cancer immunotherapy. Dr. Wu holds a Ph.D. in Immunology from the College of Medicine, National Taiwan University, and has conducted postdoctoral research at The Scripps Research Institute in the United States. He specializes in antibody engineering and cancer immunotherapy. His newly developed drug, UCT021, is an innovative antibody-drug conjugate (ADC) targeting GRP78, designed to treat acute myeloid leukemia (AML) by precisely eliminating AML cells. This lecture will enhance the understanding of the latest technological advancements among faculty and students.
**Lecturer:** Dr. Chia-Cheng Wu
**Highest Degree:** Ph.D., Institute of Immunology, College of Medicine, National Taiwan University
**Current Position:** CEO, UoST Biopharma
**Previous Positions:** Director, Institute of Biopharmaceuticals, Biotechnology Development Center (Foundation); Director, Taiwan Antibody Association; Secretary-General, Taiwan Antibody Association
**Professional Expertise and Achievements:**
- Led/Executed multiple large-scale biomedical projects funded by the government from 2017 to 2019, with annual budgets of approximately NT$360–400 million. These projects included 11 antibody/next-generation antibody drug development initiatives, as well as 4 platform establishment and formulation/process development projects.
- Inventor of 10 new patents (applied/awarded).
- Recipient of the DCB “Technology Innovation Award” in 2014, 2016, and 2017.
- Winner of the 16th National Innovation Award in 2019.
**Title:** UCT021, An Innovative Antibody Drug Conjugate Targeting GRP78 for Acute Myeloid Leukemia Therapy
**Date:** Friday, April 24, 2026
**Time:** 12:10 PM – 1:40 PM
**Venue:** First Teaching and Discussion Room, Central Campus
**Notes:**
1. This workshop is recognized under Tzu Chi University is “Guidelines for Supporting the Overall Development of Faculty,” counting as one instance of faculty professional development.
2. Please register via the university administrative system [Event Code: 11500436].
3. Limited complimentary light meals will be provided to those who complete registration and attend on time.
4. For registration by external participants, please email: fangting@gms.tcu.edu.tw, providing your name and affiliation.
|
|